-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Downgrades LENZ Therapeutics to Neutral, Lowers Price Target to $12

Benzinga·05/12/2026 10:23:58
Listen to the news
Piper Sandler analyst Biren Amin downgrades LENZ Therapeutics (NASDAQ:LENZ) from Overweight to Neutral and lowers the price target from $39 to $12.